View Older Stories View More Recent Stories

May 22, 2023 04:05PM Blueprint Medicines (BPMC) Announces FDA Approval of AYVAKIT
May 22, 2023 04:04PM FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis
May 4, 2023 05:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023 07:00AM Blueprint Medicines Reports First Quarter 2023 Results
Apr 26, 2023 10:00AM Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting
Apr 20, 2023 04:01PM Blueprint Medicines to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
Apr 11, 2023 08:00AM Blueprint Medicines to Present at Upcoming Investor Conferences
Apr 5, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 28, 2023 04:06PM Blueprint Medicines (BPMC) says FDA lifts partial clinical hold on BLU-222
Mar 28, 2023 04:05PM Blueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222
Mar 7, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 26, 2023 03:00PM Blueprint Medicines Presents Registrational Data from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Feb 23, 2023 08:01AM Blueprint Medicines (BPMC) to Regain Global Rights to GAVRETO from Roche
Feb 23, 2023 08:00AM Blueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from Roche
Feb 16, 2023 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
Feb 10, 2023 08:00AM Blueprint Medicines (BPMC) Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
Feb 10, 2023 08:00AM Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222
Feb 9, 2023 08:00AM Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
Feb 7, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 3, 2023 09:00AM Blueprint Medicines to Present Positive Data from PIONEER Trial of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis at 2023 AAAAI Annual Meeting
Jan 23, 2023 08:01AM Blueprint Medicines (BPMC) Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Jan 23, 2023 08:00AM Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Jan 6, 2023 09:01AM Blueprint Medicines (BPMC) Appoints John Tsai to its Board
Jan 6, 2023 09:00AM Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors
Jan 5, 2023 08:06AM Blueprint Medicines (BPMC) Provides 2023 Portfolio Goals to Achieve Precision at Scale
Jan 5, 2023 08:00AM Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale
Jan 4, 2023 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 11, 2022 05:30PM Blueprint Medicines Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis
Dec 5, 2022 05:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 22, 2022 04:37PM Blueprint Medicines (BPMC) Submits sNDA to FDA for AYVAKIT for Treatment of Indolent Systemic Mastocytosis
Nov 22, 2022 04:36PM Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis
Nov 9, 2022 04:01PM Blueprint Medicines to Present at Upcoming Investor Conferences
Nov 4, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2022 09:00AM Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting
Nov 1, 2022 08:00AM Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
Oct 19, 2022 08:00AM Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022
Oct 6, 2022 04:30PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 6, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 24, 2022 08:02AM Blueprint Medicines (BPMC) Reports Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
Aug 24, 2022 08:00AM CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis
Aug 17, 2022 07:08AM Blueprint Medicines (BPMC) Announces Positive Top-line Results from PIONEER Trial of AYVAKIT in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
Aug 17, 2022 07:00AM Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoi
Aug 8, 2022 06:15AM Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
Aug 4, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 2, 2022 07:00AM Blueprint Medicines Reports Second Quarter 2022 Results
Jul 26, 2022 08:00AM Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
Jul 14, 2022 04:15PM Blueprint Medicines Publishes Inaugural Corporate Responsibility Report
Jul 7, 2022 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 30, 2022 07:16AM Blueprint Medicines (BPMC) Enters $1.25B Strategic Financing Collaborations with Sixth Street and Royalty Pharma (RPRX)
Jun 30, 2022 07:15AM Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma
View More Recent Stories View Older Stories